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ABSTRACT: Following on our 60-year research on the
chemical constituents of the rain forest trees Galbulimima
belgraveana and Galbulimima baccata, we report the isolation
of seven new alkaloids: GB14 (14), GB22 (15), GB25 (16),
GB21 (17), GB23 (18), GB24 (19), and GB26 (20). Their
structures were elucidated by a combination of spectroscopic
analyses and single-crystal X-ray crystallography, as well as
structure degradation and interconversion. The newly isolated
alkaloids are precursors or derivatives of the known family
members from our early studies and could be intermediates in the biosynthesis of the Galbulimima alkaloids. Therefore, the
present study has expanded the range of structures in this family of alkaloids and provided some missing links in the biosynthetic
sequences.
■ INTRODUCTION
Galbulimima belgraveana and Galbulimima baccata are large
aromatic evergreen trees that grow in thick mountain
rainforests in Papua New Guinea, Indonesia, and Northern
Australia.1 These trees are a hallucinogenic plant and have been
used by native tribes in religious ceremonies and treated as
herbal medicines to induce deep sleep or relieve abdominal
pains.2 The phytochemistry of both G. belgraveana and G.
baccata has been extensively studied and revealed that the bark
of both species is a rich source of alkaloids, viz., Galbulimima
alkaloids.3 The pioneering research conducted by us led to the
isolation of 28 Galbulimima alkaloids, 22 of which have been
characterized via a combination of spectroscopic analysis,
structure degradation, and interconversion, as well as semisyn-
thesis.4 Following the early studies, we have reported the
structures assigned to five of the remaining six alkaloids and
two new family members in 20095 and 2011,6 leading to 29
members that have been characterized. Although significant
structural diversity exists within this alkaloid family, all the
members possess a trans-decalin system and a piperidine ring,
and they could be classified into four distinct subgroups
(representative structures of four classes are shown in Figure
1). Most of the class I alkaloids (nine members) possess a δ-
lactone annulated to a trans-decalin moiety, represented by
himbacine (1) and himgravine (2) from early studies. The
newly isolated class I members GB18 (3) and GB20 (4) slightly
differ as the carbon tether connecting the trans-decalin and the
piperidine ring is linked with C-7. The class II compounds (15
members) are structurally more complex in terms of their fused
ring systems, and the piperidine ring is linked to the decalin
moiety via an additional bond. Himandrine (5), himandridine
(6), GB12 (7), and GB1 (8) are typical class II members, and
this subgroup contains approximately one-half of all Galbuli-
mima alkaloids isolated and characterized so far. The class III
members (three alkaloids) differ from class II ones on the
connectivity between the piperidine unit and the trans-decalin
system, and this subclass includes GB13 (9), himbadine (10),
and himgaline (11). The class IV members (two alkaloids), also
known as “Miscellaneous” alkaloids, structurally vary from the
other classes and have little resemblance to each other,
represented by GB17 (12) and GB16 (13).7
Detailed biological evaluation of Galbulimima alkaloids
revealed some fascinating properties, for instance, the class I
alkaloid himbacine (1) was found to be a strong muscarinic
receptor antagonist.8 Because antagonists of the muscarinic
receptors elevate the level of acetylcholine, this means that
himbacine could act as a potential therapeutics for the
treatment of Alzheimer’s disease.9 Moreover, structural
modification of himbacine led to the development of vorapaxar
(SCH 530348), a thrombin receptor antagonist, which has
been approved by the FDA to treat patients with peripheral
arterial disease in 2014.10 Because of their fascinating structural
features as well as potential pharmacological applications, the
Galbulimima alkaloids have attracted considerable attention
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from the synthetic community. The total syntheses of eight
representative members, that is, himbacine,11 himbeline,11a
himandravine,12 himandrine,13 GB13,14 himgaline,14c,d GB16,14f
and GB17,12b,15 have been completed by creative synthetic
endeavor.7,16 Meanwhile, the biogenesis of the Galbulimima
alkaloids has been discussed extensively within these synthetic
works.17,14b
Our continuing efforts to explore the chemical constituents
from G. belgraveana and G. baccata have led to some interesting
findings. Herein, we report the isolation and structure
elucidation of seven new alkaloids, namely, GB14 (14), GB22
(15), GB25 (16), GB21 (17), GB23 (18), GB24 (19), and
GB26 (20). Compounds 14−16 (Figure 2) were obtained from
the extracts of the bark, whereas the remaining four alkaloids
17−20 (Figure 3) were isolated from the methanol extracts of
fresh leaves of G. baccata. GB14 (14), GB25 (16), and
GB24 (19) are new class II members, GB22 (15) is an
oxygenated derivative of class III alkaloid himdabine (10), and
GB21 (17) could be regarded as the precursor of class I
alkaloids GB21 (4) and GB26 (20), whereas GB23 (18) is a
precursor of known class I member himgravine (2).
Figure 1. Representative structures of the Galbulimima alkaloids.
Figure 2. Structures of the new alkaloids isolated from bark extracts.
Figure 3. Structures of the new alkaloids isolated from leaf extracts.
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■ RESULTS AND DISCUSSION
Like all the Galbulimima alkaloids identified so far, the new
compounds 14−16 were isolated from the bark extracts of G.
belgraveana and G. baccata. GB14 (14) was obtained as a white
amorphous solid, which was recrystallized from methanol to
give a white crystalline solid. Its molecular formula was
determined as C22H33NO5, according to its electron ionization
mass spectrometry (HREIMS) peak at m/z 416.2438 [M +
H]+. The infrared (IR) spectrum showed two absorption bands
at 1740 and 1692, corresponding to two ester functions. The
13C NMR spectra showed GB14 to possess two ester functional
groups at C-16 and C-17 (δc 170.7 and δc 169.3) and one
tetrasubstituted double bond (δc 164.7 and δc 116.0). The
methyl signals at δH 3.74 (H-22), δH 2.03 (OAc-16), and δH
1.32 (H-1) as well as the absence of the N-methyl group
indicated that this compound could be a class II alkaloid with
an acetate function. The doublet at δH 5.61 (J = 8.5 Hz)
suggested that the acetate be located at C-16. After the
comparison of the NMR data with class II alkaloid himandrine
(5), we were then able to arrive at a gross structure 14.
Furthermore, the unequivocal stereochemical assignments
(including the absolute configuration) were confirmed via
single-crystal X-ray analysis (see the Supporting Information for
details).
The NMR spectra of GB22 were puzzling at first because
there was one benzene proton at δH 6.59 (H-17), yet no ester
or double bond signals were observed. N-Methyl at the
piperidine ring could be found at δH 1.96 (H-21); however, the
obvious upfield shift of the methyl at C-2 (δH 0.78) indicated
the presence of a benzenoid B ring. Its molecular formula
C21H29NO2 derived from HREIMS was extremely similar to
that of class III alkaloid himbadine (10) (C21H31NO2). We
concluded, therefore, that the new alkaloid was the aromatized
derivative of himbadine, and the final structure 15 as well as the
absolute configuration was determined by single-crystal X-ray
analysis (see the Supporting Information for details). To shed
more light on this transformation, various oxidation conditions
were applied on himbadine (10) with the hope of forming
GB22 directly; however, it turned out that this requires an
unusual procedure (Scheme 1). Compound 10 was oxidized by
H2SO4 in acetic anhydride to afford himbadine acetate (21) as
the major product (47%) and GB22 diacetate (22) as the
minor one (27%), and the latter compound was then
hydrolyzed to give the final target 15 in a good yield (84%).
GB25 (16) was obtained as a white amorphous solid with a
molecular formula C22H31NO4. When its NMR spectra were
compared with those of GB14 (14), it was apparent that GB25
had almost the same structural features except for the presence
of an acetate group. The structure was assigned to compound
16 and again was confirmed by single-crystal X-ray analysis (see
the Supporting Information for details).
After three new family members were identified from the
bark extracts, we then turned our attention to the alkaloid
components from the other parts that remain unexplored, that
is, the fresh leaves, to search for new members or metabolites,
which resulted in the isolation of four new alkaloids. GB21 (17)
was the first sample obtained, and it was a white, crystalline
solid with a molecular formula C21H31NO2. Structural features
from the NMR spectra include a usual piperidine ring system
lacking an N-methyl group, a trisubstituted double bond (δc
143.4, 131.4; δH 6.75, t, J = 3.7 Hz) conjugated to a lactone-
type carbonyl group (δc 169.5), and a tertiary methyl group (δH
1.01) which indicated a class I alkaloid. Fitting these data to a
GB20-like6 skeleton, we arrived at structure 17 which was
confirmed by single-crystal X-ray analysis (see the Supporting
Information for details). Our sample of GB23 (18) had a
molecular formula of C21H31NO2, and its NMR spectra were
quite similar to that of class I alkaloid (+)-himgravine except for
the absence of the N-methyl group. We concluded, therefore,
that the new alkaloid was (+)-desmethylhimgravine, whose
structure was again confirmed by single-crystal X-ray analysis
(see the Supporting Information for details).
The third new alkaloid obtained was GB24 (19), a white
amorphous solid, and its molecular formula was determined as
C22H29NO4. NMR spectra revealed one ketone (δc 196.2)
being conjugated to a tetrasubstituted double bond (δc 168.4
and δc 121.3) and one ester carbonyl group (δc 173.4). We
assumed the methyl signal (δH 3.85) to be a methyl ester that
was attached to the double bond. The spectra varied from the
class IV member GB165 (13) to the typical class III member
GB13 (9) which possessed α,β-unsaturated ketone. Compar-
isons of both the 1H and 13C NMR spectra with those of GB25
(16) showed the best similarities. However, the structure could
not be elucidated because of insufficient functional signals.
Fortunately, treatment of the sample with HCl produced a salt
that appeared to be a good crystal, and the single-crystal X-ray
analysis confirmed the structure to be compound 19 (see the
Supporting Information for details). To provide more materials
for further biological evaluation, we conducted semisyntheses of
GB24 (19), GB25 (16), and GB14 (14), and the three closely
related members, from class II alkaloid GB12 (7), were
obtained by early studies (Scheme 2). Hydrolyzing the
triacetate of compound 7 in K2CO3 and methanol conditions
afforded triol 23 in a good yield, and the allylic hydroxy group
was then oxidized selectively by MnO2 to produce ketone 24
(98%). Removal of the hydroxy group at the C-14 position was
investigated by radical deoxygenation; however, the required
thiocarbonylimidazolide compound 25 could only be prepared
by a solid-state reaction with thiocarbonyldiimidazole (TCDI)
in the presence of 3 equiv dimethylaminopyridine (DMAP) at
80 °C.18 The so-obtained intermediate 25 was then submitted
to a radical cleavage with tri-n-butyltin hydride (Bu3SnH) and
azabisisobutyronitrile (AIBN) in toluene to give the expected
GB24 (19) in a 50% yield and a reduced product 24 (20%).
GB24 was then reduced by NaBH4 to afford GB25 (15) in a
75% yield, and the latter compound was then converted to
GB14 (14) via the acetylation condition (71%).
Scheme 1. Semisynthesis of GB22 (15) from
Himbadine (10)
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The last alkaloid GB26 had a molecular formula C21H33NO4,
and it was the most polar member during column
chromatography, assuming it possessed some polar functional
groups. It had the same carbon number with GB21 (17);
furthermore, NMR spectra showed some similarities with those
of 17: a usual piperidine ring system lacking an N-methyl
group, a trisubstituted double bond (δc 137.3, 136.8; δH 6.01, s
at C-16 and C-17) conjugated to a carbonyl group (δc 173.9, C-
21), and a tertiary methyl group (δH 1.03). However,
13C NMR
indicated that there are four quaternary carbons (δc 173.9,
136.8, 81.4, and 67.6), and the proton NMR suggested that
there are two tertiary hydroxyl groups at C-15 (δH 6.22, δc
67.6) and C-19 (δH 5.60, δc 81.4). After comparing the data
with those of GB206 (4), we then arrived at the structure of
GB21 (17) possessing an additional hydroxyl at C-15, and the
second tertiary hydroxyl at C-19 could be derived from the ring
opening of lactone, which also resulted in the release of
carboxylic acid at C-17, all of those could attribute to the
significant polarity of this compound. With the combined data,
we finally came to a unique structure 20. Initially, we wanted to
confirm the proposed structure via single-crystal X-ray analysis;
however, evaporation of solutions of this sample in various
solvent systems failed to afford a suitable material for single-
crystal X-ray analysis. Then, this compound was treated with
HCl (4 M solution in dioxane) followed by being dissolved in a
CH2Cl2/MeOH/EtOAc system. Upon evaporating, a material
suitable for single-crystal X-ray analysis (see the Supporting
Information for details) was obtained, which was determined to
be diene 26, an eliminated derivative of compound 20 (Scheme
3). Therefore, the final structure as well as the absolute
configuration of compound 26 was confirmed. However,
because of the very small amounts of the material obtained,
no other spectral data could be acquired on this diene.
There has been a great deal of speculation about the
biogenesis of the Galbulimima alkaloids, and in most of the
postulated biosyntheses, the putative polyene 27 (Figure 4)
serves as a common precursor and undergoes regiodivergent
Diels−Alder cycloaddition to establish the alkaloid skeleton.
This hypothesis has been supported by elegant biomimetic
syntheses of the class I member himbadine (1),11g class III
alkaloid GB13 (9),14b and class IV member GB17 (12).12b We
believe that an intramolecular [4 + 2] cycloaddition of polyene
27 following path a (Figure 4) would lead to intermediate 30,
which underwent an imine reduction, and lactone formation
process could deliver GB23 (18) and then himgravine (2).
Alternatively, coiling of polyene 27 in the cycloaddition process
following path b would afford intermediate 31 with different
stereochemistry. A Michael reaction on the latter compound
would deliver a new cyclopentanone compound 32, which
could be converted to enone 33 after proton shift and the
oxidation process. An enamine-based aldol reaction between
the cyclopentanone and the piperidine ring would then result in
pentacycle 34, and in their total syntheses of himandrine (5)
and GB13 (9), Movassaghi13 and Evans14d showed that such a
sequence was feasible. This common intermediate 34 en route
to class II members passes through GB24 (19) and to other
ones, that is, GB14 (14), GB25 (19), himandrine (5),
himandridine (6), GB12 (7), and GB1 (8) after decarbox-
ylation, oxidation, and other associated processes. Compound
31 could also serve as a precursor to class I alkaloid GB21 (17)
after a reduction/cyclization sequence, and the latter
compound could then be oxidized followed by acetylation to
give GB20 (4). Hydrolysis on both the lactone ring and the
acetamide on GB20 would deliver the new member GB26 (20).
The biosynthesis of class IV member GB17 (12) requires an
intramolecular Diels−Alder reaction (IMDA) on the polyene
structure such as 35 that could be derived from polyene 27 via
path c. In this way, the intermediate 36 from which an
azachrysene framework could plausibly be formed, it would
serve as a precursor to GB17 (12). In a recent biomimetic total
synthesis of GB17, Thomson12b employed a precursor similar
to that of 35, and the computational investigations indicated
that because of the competing orbital interaction and distortion
energies, such an IMDA process showed low regioselectivity.
■ CONCLUSIONS
The work detailed here has expanded the range of structures in
the Galbulimima alkaloid family, although no new skeleton was
found. Most of the new members isolated could be regarded as
metabolites or precursors of the known alkaloids. Nevertheless,
Scheme 2. Semisyntheses of GB25 (19), GB24 (16), and
GB14 (14) from GB12 (7)
Scheme 3. Derivatization of Compound 20, Leading to
Diene 26
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the isolation and identification of these new family members
have shed more light on the biosynthesis route of the
Galbulimima alkaloids, which has been proved by the
semisynthesis of GB22 (15) and the interconversions of
GB14 (14), GB25 (16), and GB24 (19). The present work has
also found some missing links in the biosynthetic sequences.
Our current efforts are focused on undertaking a comprehen-
sive biological evaluation of the new alkaloids we have isolated
to date. Results will be reported in due course.
■ EXPERIMENTAL SECTION
General Experimental Protocols. All reagents and
solvents were of commercial grade and purified prior to use
when necessary. Thin-layer chromatography was performed on
aluminum-backed 0.2 mm thick silica gel 60 F254 plates as
supplied by Merck. Visualization was accomplished with UV
light and/or the use of ninhydrin or potassium permanganate
solution followed by brief heating with a heat gun. Flash
chromatographic separations were carried out with silica gel 60
(40−63 μm) as the stationary phase and using the solvents
indicated. IR spectra (νmax) were recorded on a PerkinElmer
1800 Series Fourier transform infrared spectrometer. Samples
were applied to KBr plates as CDCl3 solutions followed by
generous air drying. Melting points were measured on an
Optimelt automated melting point system and are uncorrected.
1H and 13C NMR spectra were recorded on a Bruker
spectrometer operating at 400 MHz for proton and 100 MHz
for carbon nuclei. Chemical shifts are reported in parts per
million relative to residual solvent peaks as an internal standard
at the following chemical shifts (1H and 13C, respectively): 7.26
and 77.0 ppm for CDCl3. Data are reported as follows:
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet,
q = quartet, p = pentet, qd = quartet of doublets, br = broad,
and m = multiplet), coupling constant (Hz), integration, and
assigned position. Low-resolution electrospray ionization (ESI)
mass spectra were recorded on a single quadrupole liquid
chromatograph−mass spectrometer, and high-resolution meas-
urements were recorded on a time-of-flight instrument. Low-
and high-resolution EI mass spectra were recorded on a
magnetic sector machine. Wherever necessary, reactions were
performed under a nitrogen atmosphere.
Plant Materials. G. belgraveana bark was acquired at Aiyura
on the eastern highlands of New Guinea in August 1951. A
voucher specimen (sample no. 5091) was housed within the
Commonwealth Scientific and Industrial Research Organization
(C.S.I.R.O.), Australia. G. baccata bark was collected near
Boonjie, North Queensland, in August 1947. A voucher
specimen (sample no. 4273) was housed within the
C.S.I.R.O. The plant materials were identified by Messrs. J.
G. Tracey and L. J. Webb at C.S.I.R.O. and Mr. J. S.
Womersley, Department of Forests, Lae. G. baccata leaf
material was obtained from the Royal Botanic Gardens, Sydney,
NSW, Australia. The leaves were harvested on May 15, 2012,
and a voucher specimen (catalogue number: 05-79352) was
deposited at the Royal Botanic Gardens, Sydney, NSW,
Australia. The plant materials were identified by Dr. Benjamin
Thomas.
Figure 4. Biosynthetic speculations of Galbulimima alkaloids.
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Isolation of Compounds 9−15. Compounds 9−11 were
isolated from the bark extracts from G. belgraveana and G.
baccata left by our early studies.4 The crude bark extracts were
obtained by using the following procedure: the shade-dried
milled bark (10 kg) was exhausted with cold methanol (20 L)
three times before being filtered, and the filtrate was
concentrated under reduced pressure. The crude bark extracts
were suspended in 5% NaOH aqueous solution (3 L) and were
extracted with ether (3 × 3 L). The dark aqueous alkaline
solution was discarded, and the organic layer was then extracted
with 4% HCl (3 × 3 L). The acid extract was washed with ether
(3 × 1 L), basified with ammonia to reach a pH value of 10, and
then the liberated bases were extracted with chloroform (3 × 3
L). Evaporation of the dried organic layer gave a thick brown
oil, which was subjected to gradient chromatography or
recrystallization to yield the previously reported Galbulimima
alkaloids. The unseparated mixtures were then stored under
ambient temperature at the Research School of Chemistry and
the Australian National University since 1970s. Gradient
chromatography (silica, 1:10:0.1 to 5:10:0.1 v/v/v methanol/
dichloromethane/NH3 elution) on these mixtures afforded new
compounds 14 (35 mg), 15 (18 mg), and 16 (26 mg).
Compounds 17−20 were obtained from the fresh leaf extracts
from G. baccata using the following procedure: the fresh leaves
of G. baccata (3 kg) were treated with liquid nitrogen and then
crushed in the meantime, and after being warmed to room
temperature, the residues were percolated with methanol (10
L) three times at 25 °C. The solution was then filtered, and the
filtrates combined were concentrated under reduced pressure.
The crude extract (300 g) was suspended in 5% NaOH
aqueous solution (1 L) and was extracted with ether (3 × 1 L).
The separated organic layer was further extracted with 4% HCl
(3 × 1 L). The acid extract was washed with ether (3 × 500
mL), basified with ammonia to reach a pH value of 10, and
then extracted with dichloromethane (3 × 500 mL).
Evaporation of the dried organic layer gave a thick brown oil
(2.7 g), which was subjected to gradient chromatography
(silica, 1:10:0.1 to 5:10:0.1 v/v/v methanol/dichloromethane/
NH3 elution) to afford the three major fractions A (450 mg), B
(670 mg), and C (810 mg). Further purification on fraction A
using 1:10:0.1 v/v/v methanol/dichloromethane/NH3 elution
afforded compound 17 (56 mg) and compound 118 (120 mg);
purification on fraction C using 2:10:0.1 v/v/v methanol/
dichloromethane/NH3 elution gave compound 19 (35 mg); the
most polar fraction C was purified several times by 3:10:0.1 v/
v/v methanol/dichloromethane/NH3 elution to afford com-
pound 20 (265 mg).
GB14 (14). A white amorphous solid, and a sample suitable
for single-crystal X-ray analysis was recrystallized from
methanol, mp 112−114 °C, [α]D20 = −16.3 (c 0.22, CHCl3).
1H NMR (400 MHz, CDCl3): δ 5.61 (d, J = 8.5 Hz, 1H, H-16),
4.59 (s, 1H, OH-20), 3.74 (s, 3H, H-22), 3.45 (m, 1H, H-6),
3.31 (m, 1H, H-2), 2.30 (m, 1H, H-8), 2.21−2.17 (complex m,
1H), 2.13−2.07 (complex m, 2H), 2.03 (s, 3H, OAc-16), 1.98
(m, 1H), 1.89−1.83 (complex m, 2H), 1.83−1.72 (complex m,
4H), 1.69−1.60 (complex m, 3H), 1.55 (complex m, 1H),
1.47−1.42 (complex m, 2H), 1.32 (d, J = 7.2 Hz, 3H, H-1),
1.25−1.12 (complex m, 2H), 1.10−0.98 (complex m, 1H). 13C
NMR (100 MHz, CDCl3): δ 170.7 (OAc-16), 169.3 (C18),
164.7 (C19), 116.0 (C17), 80.9 (C16), 73.9 (C20), 69.3 (C9),
68.0 (C6), 55.6 (C2), 52.0 (C22), 50.3 (C5), 49.0 (C15), 44.7
(C10), 44.6 (C21), 41.0 (C7), 37.3 (C11), 31.7 (C8), 27.6
(C14), 27.4 (C13), 26.4 (C12), 25.9 (C3), 25.5 (C4), 24.1
(OAc-16), 21.1 (C1). IR (KBr) νmax: 3451, 2930, 2855, 1740,
1692, 1436, 1371, 1262, 1233, 1158, 1039, 731 cm−1. MS (ESI,
+ve) m/z: 416 ([M + H]+, 100%), 438 ([M + Na]+, 12).
HRMS: [M + H]+ calcd for C24H34NO5, 416.2437; found,
416.2438.
GB22 (15). A pale-yellow amorphous solid, treatment with
HCl in dioxane gave its HCl salt, and a sample suitable for
single-crystal X-ray analysis was recrystallized from methanol,
mp >250 °C (decomp.), [α]D
20 = +84 (c 1.3, MeOH). 1H NMR
(400 MHz, CDCl3): δ 6.59 (s, 1H, H-17), 3.11 (m, 1H, H-6),
2.76 (m, 1H, H-2), 2.68−2.64 (complex m, 1H), 2.61−2.52
(complex m, 3H), 2.22 (complex m, 1H), 2.13 (d, J = 9.7 Hz,
1H), 2.08 (m, 1H), 2.02−1.99 (m, 1H), 1.98−1.95 (complex
m, 1H), 1.96 (s, 3H, H-21), 1.78−1.71 (complex m, 4H),
1.68−1.63 (complex m, 1H), 1.47−1.37 (complex m, 3H),
1.34−1.31 (complex m, 1H), 0.78 (d, J = 6.3 Hz, 3H, H-1). 13C
NMR (100 MHz, CDCl3): δ 152.1 (C16), 144.7 (C18), 137.0
(C9), 131.8 (C10), 121.9 (C15), 106.8 (C17), 82.1 (C19),
60.2 (C6), 55.6 (C2), 50.3 (C5), 43.5 (C20), 38.8 (C7), 34.7
(C11), 30.6 (C8), 29.1 (C14), 25.9 (C13), 23.3 (C12), 22.8
(C3), 22.7 (C4), 21.0 (C21), 20.3 (C1). IR (KBr) νmax: 3280,
2929, 2857, 1683, 1601, 1445, 1294, 1245, 1197, 1104, 1077,
907, 730, 647 cm−1. MS (EI, +70 eV) m/z: 327 (M+•, 43%),
311 (40), 310 (100). HRMS: M+• calcd for C21H29NO2,
327.2198; found, 327.2197.
GB25 (16). A white amorphous solid, treatment with HCl in
dioxane gave its HCl salt, and a sample suitable for single-
crystal X-ray analysis was recrystallized from methanol, mp
>250 °C (decomp.), [α]D
20 = −4.7 (c 1.7, CHCl3). 1H NMR
(400 MHz, CDCl3): δ 4.83 (s, 1H, OH-20), 4.14 (dd, J = 8.3
and 4.6 Hz, 1H, H-16), 3.86 (s, 3H, H-22), 3.43 (m, 1H, H-6),
3.29 (m, 1H, H-2), 2.36 (d, J = 4.7 Hz, 1H, H-8), 2.32−2.22
(complex m, 2H), 2.19−2.17 (complex m, 1H), 2.09−1.93
(complex m, 3H), 1.89−1.71 (complex m, 5H), 1.68−1.59
(complex m, 2H), 1.54 (complex m, 1H), 1.45 (td, J = 12.6 and
3.5 Hz, 1H), 1.36 (complex m, 1H), 1.32 (d, J = 7.2 Hz, 3H, H-
1), 1.27−1.20 (complex m, 2H), 1.00−0.90 (complex m, 1H).
13C NMR (100 MHz, CDCl3): δ 169.6 (C18), 163.6 (C19),
119.0 (C17), 80.8 (C16), 72.4 (C20), 69.2 (C9), 68.3 (C6),
55.6 (C2), 52.3 (C22), 50.4 (C5), 48.9 (C15), 44.8 (C10), 44.7
(C21), 42.1 (C7), 37.3 (C11), 32.3 (C8), 27.5 (C14), 27.5
(C13), 26.5 (C12), 26.0 (C3), 25.6 (C4), 24.1 (C1). IR (KBr)
νmax: 3436, 2931, 2854, 1687, 1456, 1371, 1260, 1229, 1181,
1138, 1078, 1038, 967, 910, 731, 642 cm−1. MS (ESI, +ve) m/z:
374 ([M + H]+, 100%), 396 ([M + Na]+, 32). HRMS: [M +
H]+ calcd for C22H32NO4, 374.2331; found, 374.2331.
GB21 (17). A white crystalline solid, mp 135−138 °C, [α]D20
= −19.0 (c 0.4, CHCl3). 1H NMR (400 MHz, CDCl3): δ 6.75
(t, J = 3.7 Hz, 1H, H-16), 2.75−2.67 (complex m, 2H, H-6 and
H-18), 2.60 (m, 1H, H-2), 2.11 (m, 2H), 2.00−1.92 (complex
m, 3H), 1.80−1.70 (complex m, 5H), 1.60 (s, 3H, H-20),
1.59−1.50 (complex m, 1H), 1.42−1.35 (complex m, 1H),
1.34−1.15 (complex m, 6H), 1.13−1.08 (complex m, 1H), 1.01
(d, J = 6.1 Hz, 3H, H-1), 0.90−0.75 (complex m, 2H). 13C
NMR (100 MHz, CDCl3): δ 169.5 (C21), 143.4 (C16), 131.4
(C17), 92.6 (C19), 56.9 (C2), 55.7 (C6), 52.9 (C7), 52.5
(C18), 45.0 (C15), 43.7 (C10), 43.2 (C9), 36.9 (C3), 33.8
(C14), 33.7 (C8), 31.6 (C13), 31.5 (C5), 28.3 (C11), 26.8
(C12), 26.1 (C20), 24.7 (C4), 23.1 (C1). IR (KBr) νmax: 2922,
2853, 1755, 1665, 1445, 1379, 1247, 1171, 1090, 1049, 1019,
924, 722 cm−1. MS (EI, +70 eV) m/z: 329 (M+•, 5%), 98
(100). HRMS: M+• calcd for C21H31NO2, 329.2355; found,
329.2355.
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GB23 (18). A white amorphous solid, treatment with HCl in
dioxane gave its HCl salt, and a sample suitable for single-
crystal X-ray analysis was recrystallized from methanol, mp
>250 °C (decomp.), [α]D
20 = +6.4 (c 0.9, CHCl3).
1H NMR
(400 MHz, CDCl3): δ 6.67 (t, J = 3.1 Hz, 1H, H-16), 5.74 (dd,
J = 15.3 and 6.6 Hz, 1H, H-7), 5.22 (dd, J = 15.3 and 10.2 Hz,
1H, H-8), 4.32 (dq, J = 9.3 and 6.1 Hz, 1H, H-19), 3.58 (m,
1H, H-6), 3.10 (m, 1H, H-2), 2.69 (m, 1H, H-18), 2.34 (q, J =
10.2 Hz, 1H, H-9), 2.05 (m, 1H, H-15), 1.88 (m, 1H), 1.82−
1.74 (complex m, 3H), 1.72−1.66 (complex m, 2H), 1.66−1.59
(complex m, 2H), 1.58−1.49 (complex m, 2H), 1.42 (d, J = 6.0
Hz, 3H, H-20), 1.30−1.15 (complex m, 4H), 1.11 (d, J = 6.4
Hz, 3H, H-1), 0.87 (td, J = 12.2 and 3.1 Hz, 1H), 0.77 (m, 1H).
13C NMR (100 MHz, CDCl3): δ 169.4 (C21), 141.4 (C16),
136.8 (C7), 130.6 (C8), 129.7 (C17), 77.6 (C19), 52.9 (C6),
46.7 (C2), 46.3 (C9), 44.8 (C15), 43.5 (C10), 40.4 (C1), 32.6
(C5), 32.5 (C3), 31.2 (C11), 31.1 (C14), 26.3 (C12), 26.0
(C13), 21.4 (C4), 20.9 (C20), 19.7 (C1). IR (KBr) νmax: 2922,
2851, 1755, 1683, 1445, 1382, 1218, 1047, 1026, 980, 903, 729
cm−1. MS (EI, +70 eV) m/z: 329 ([M]+•, 30%), 314 (80), 218
(22), 164 (30), 111 (45), 98 (100). HRMS: M+• calcd for
C21H31NO2, 329.2355; found, 329.2357.
GB24 (19). A white amorphous solid, treatment with HCl in
dioxane gave its HCl salt, and a sample suitable for single-
crystal X-ray analysis was recrystallized from methanol, mp
>250 °C (decomp.), [α]D
20 = +216.0 (c 1, CHCl3).
1H NMR
(400 MHz, CDCl3): δ 3.84 (s, 3H, H-22), 3.46 (m, 1H, H-6),
3.37 (m, 1H, H-2), 2.77 (s, 1H), 2.54 (ddd, J = 12.6, 10.8 and
3.4 Hz, 1H), 2.39 (dm, J = 13.2 Hz, 1H), 2.30−2.19 (complex
m, 2H), 2.12 (m, 1H), 2.01−1.88 (complex m, 3H), 1.86−1.78
(complex m, 3H), 1.76−1.70 (complex m, 2H), 1.66 (d, J =
11.2 Hz, 1H), 1.61 (d, J = 10.9 Hz, 1H), 1.56−1.43 (complex
m, 1H), 1.35−1.30 (complex m, 2H), 1.24 (d, J = 7.2 Hz, 3H,
H-1), 1.22−1.14 (complex m, 1H), 1.10−1.00 (complex m,
1H). 13C NMR (100 MHz, CDCl3): δ 196.2 (C16), 173.4
(C18), 168.3 (C19), 121.3 (C17), 80.3 (C20), 69.0 (C9), 65.5
(C6), 55.2 (C2), 52.5 (C22), 50.4 (C5), 49.4 (C15), 46.8
(C10), 46.4 (C21), 43.7 (C7), 37.1 (C11), 27.6 (C8), 27.5
(C14), 27.1 (C13), 26.2 (C12), 26.1 (C3), 25.3 (C4), 24.2
(C1). IR (KBr) νmax: 3470, 2936, 2858, 1732, 1650, 1448, 1370,
1298, 1273, 1238, 1171, 1134, 1072, 1031, 989, 908, 730, 646
cm−1. MS (ESI, +ve) m/z: 372 ([M + H]+, 100%), 394 ([M +
Na]+, 25). HRMS: [M + H]+ calcd for C22H30NO4, 372.2175;
found, 372.2173.
GB26 (20). A yellow amorphous solid, [α]D
20 = −51 (c 1,
CHCl3).
1H NMR (400 MHz, CDCl3): δ 6.22 (broad s, 1H,
OH-15), 6.01 (s, 1H, H-16), 5.60 (broad s, 1H, OH-19), 3.02
(d, J = 11.3 Hz, 1H, H-18), 2.74 (dm, J = 9.4 Hz, 1H, H-6),
2.65 (m, 1H, H-2), 2.13−2.04 (complex m, 1H), 2.00−1.92
(complex m, 1H), 1.89−1.84 (complex m, 1H), 1.76−1.60
(complex m, 7H), 1.55−1.45 (complex m, 5H), 1.40−1.35
(complex m, 1H), 1.32 (s, 3H, H-20), 1.28−1.06 (complex m,
5H), 1.03 (d, J = 6.4 Hz, 3H, H-1), 0.94−0.82 (complex m,
1H). 13C NMR (100 MHz, CDCl3): δ 173.9 (C21), 137.3
(C16), 136.8 (C17), 81.4 (C19), 67.6 (C15), 55.8 (C6), 52.3
(C2), 51.2 (C18), 48.7 (C10), 46.1 (C7), 37.5 (C3), 35.3
(C9), 35.2 (C14), 31.9 (C8), 27.7 (C13), 26.2 (C5), 26.1
(C20), 25.3 (C11), 25.1 (C12), 23.0 (C1), 21.4 (C4). IR
(KBr) νmax: 3332, 2926, 2856, 1754, 1662, 1638, 1604, 1443,
1378, 1217, 1195, 1128, 1016, 961, 918, 731 cm−1. MS (EI,
−70 eV) m/z: 362 ([M − H]+, 5%), 345 ([M − H2O]+, 10),
168 (30), 98 (100). HRMS: [M − H]+ calcd for C21H32NO4,
362.2331; found, 362.2339.
Specific Chemical Transformations. Compounds 21
and 22. A magnetically stirred mixture of himbadine (10) (1.5
g, 4.55 mmol) in acetic anhydride (50 mL) was treated with
98% sulfuric acid (0.5 mL). The solution was heated at 80 °C
for 36 h under nitrogen atmosphere. Acetic anhydride was
distilled off under reduced pressure, and the residue was then
dissolved in dichloromethane (100 mL) and basified by NaOH
(50 mL of a 10% aqueous solution). The organic layers were
dried (Na2SO4), filtered, and concentrated under reduced
pressure. The resulting brown residue was subjected to
chromatography (silica, 20:1 v/v CH2Cl2/MeOH elution) to
afford two fractions. Concentration of fraction A (Rf = 0.9) gave
himbadine acetate 21 (0.8 g, 47%) as a yellow oil, [α]D
20 = −4.6
(c 1.8, CHCl3).
1H NMR (400 MHz, CDCl3): δ 6.00 (d, J = 2.2
Hz, 1H, H-17), 3.21 (dt, J = 11.4 and 2.4 Hz, 1H, H-2), 3.06
(m, 1H), 2.54−2.51 (m, 2H), 2.36−2.31 (m, 1H), 2.28−2.21
(complex m, 2H), 2.17 (s, 3H, H-21), 2.08 (s, 3H, H-19),
1.93−1.88 (complex m, 1H), 1.86−1.82 (complex m, 5H),
1.73−1.71 (complex m, 1H), 1.59−1.54 (complex m, 1H),
1.50−1.43 (complex m, 1H), 1.39−1.28 (complex m, 3H),
1.26−1.20 (complex m, 2H), 1.12−1.09 (complex m, 1H),
1.07−1.00 (complex m, 1H), 0.93 (d, J = 6.0 Hz, 3H, H-1). 13C
NMR (100 MHz, CDCl3): δ 201.3 (C16), 176.1 (OAc-19),
169.3 (C18), 119.2 (C17), 87.3 (C19), 62.6 (C2), 58.8 (C6),
52.6, 47.8, 46.9, 43.4, 43.2, 39.4, 33.9, 33.6, 31.6, 30.0, 26.0,
25.9, 25.1, 24.6, 22.2, 21.7 (C1). IR (KBr) νmax: 2928, 2855,
2775, 1739, 1664, 1447, 1367, 1235, 1184, 1092, 1069, 978,
868, 734, 594 cm−1. MS (EI, +70 eV) m/z: 371 (M+•, 25%),
313 (32), 312 (100). HRMS: M+• calcd for C23H33NO3,
371.2460; found, 371.2464.
Concentration of fraction B (Rf = 0.4) gave GB22 diacetate
22 (0.5 g, 27%) as a yellow oil, [α]D
20 = +102.5 (c 1.9, CHCl3).
1H NMR (400 MHz, CDCl3): δ 6.72 (s, 1H, H-17), 3.19 (m,
1H, H-6), 2.96 (m, 1H, H-2), 2.78 (d, J = 9.8 Hz, 1H), 2.69 (m,
1H), 2.64−2.57 (m, 2H), 2.54−2.48 (m, 2H), 2.44−2.40
(complex m, 1H), 2.28 (s, 3H, OAc-19), 2.09 (s, 3H, OAc-16),
2.05 (m, 1H), 1.89−1.81 (complex m, 2H), 1.79 (s, 3H, H-21),
1.77−1.72 (complex m, 4H), 1.64−1.61 (complex m, 1H),
1.39−1.25 (complex m, 3H), 0.74 (d, J = 6.1 Hz, 3H, H-1). 13C
NMR (100 MHz, CDCl3): δ 170.2 (OAc-19), 169.4 (OAC-
16), 147.4 (C16), 143.5 (C18), 140.5 (C9), 131.9 (C10), 127.5
(C15), 113.6 (C17), 89.5 (C19), 61.3 (C6), 57.5 (C2), 51.4,
40.7, 38.5, 36.8, 29.8, 29.2, 25.9, 23.5, 22.5(3), 22.5(0), 22.4,
21.9, 21.1, 20.9. IR (KBr) νmax: 2930, 2855, 2763, 1759, 1736,
1444, 1366, 1249, 1230, 1215, 1197, 1066, 1018, 910, 732, 646
cm−1. MS (ESI, +ve) m/z: 412 ([M + H]+, 100%), 434 (5).
HRMS: [M + H]+ calcd for C25H34NO4, 412.2488; found,
412.2482.
GB22 (15). A magnetically stirred mixture of compound 22
(0.3 g, 0.73 mmol) in MeOH (10 mL) was added to potassium
carbonate (0.6 g, 4.38 mmol). The reaction mixture was stirred
at 18 °C for 48 h before being concentrated under reduced
pressure. The resulting residue was subjected to chromatog-
raphy (silica, 9:1 v/v CH2Cl2/MeOH elution) to afford, after
concentration of the relevant fractions (Rf = 0.4), GB22 (15)
(0.2 g, 84%) as a pale-yellow amorphous solid. The structural
data were, in all respects, similar to those of an authentic
sample from isolation work.
Compound 23. A magnetically stirred mixture of GB12 (7)
(400 mg, 0.78 mmol) in MeOH (10 mL) was added to
potassium carbonate (540 mg, 3.88 mmol). The reaction
mixture was stirred at 18 °C for 10 h before being concentrated
under reduced pressure. The resulting white solid was subjected
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to chromatography (silica, 10:1 v/v CH2Cl2/MeOH elution) to
afford, after concentration of the relevant fractions (Rf = 0.4),
triol 23 (270 mg, 89%) as a white amorphous solid, [α]D
20 =
+36.6 (c 2.3, CHCl3).
1H NMR (400 MHz, CDCl3): δ 4.60 (d,
J = 7.9 Hz, 1H, H-16), 4.57 (broad s, 1H, OH), 3.85 (s, 3H, H-
22), 3.63 (broad s, 1H, OH), 3.50 (td, J = 10.0 and 4.3 Hz, 1H,
H-14), 3.45 (s, 1H, H-6), 3.43−3.36 (complex m, 1H, H-2),
3.29 (broad s, 1H, OH), 2.28 (ddd, J = 14.0, 6.2 and 2.6 Hz,
1H), 2.18−2.10 (complex m, 2H), 2.09−2.01 (complex m,
1H), 2.00−1.96 (complex m, 2H), 1.88−1.78 (complex m,
2H), 1.78−1.70 (complex m, 2H), 1.64−1.56 (complex m,
2H), 1.53 (d, J = 10.8 Hz, 1H), 1.48−1.37 (complex m, 2H),
1.34 (d, J = 7.1 Hz, 3H, H-1), 1.36−1.33 (complex m, 1H),
1.30−1.20 (complex m, 2H). 13C NMR (100 MHz, CDCl3): δ
169.5 (C18), 161.6 (C19), 118.0 (C17), 80.7 (C20), 77.6
(C16), 72.5 (C9), 69.2 (C14), 67.7 (C6), 55.5, 52.4, 50.0, 49.0,
48.1, 44.7, 42.4, 37.2, 35.6, 27.2, 26.6, 25.4, 24.1, 23.9. IR (KBr)
νmax: 3435, 2936, 2862, 1687, 1448, 1436, 1281, 1261, 1231,
1182, 1140, 1114, 1078, 1048, 1030, 974, 910, 878, 729, 643
cm−1. MS (ESI, +ve) m/z: 390 ([M + H]+, 100%). HRMS: [M
+ H]+ calcd for C22H32NO5, 390.2280; found, 390.2283.
Compound 24. A magnetically stirred mixture of triol 23
(400 mg, 1.03 mmol) in CH2Cl2 (30 mL) was treated with
MnO2 (887 mg, 10.2 mmol). The reaction mixture was stirred
at 18 °C for 24 h before being filtered through a pad of Celite,
the filter cake was washed with CH2Cl2 (100 mL), and the
combined filtrate was concentrated under reduced pressure.
The resulting colorless oil was subjected to chromatography
(silica, 10:1 v/v CH2Cl2/MeOH elution) to afford, after
concentration of the relevant fractions (Rf = 0.5), ketone 24
(390 mg, 98%) as a white amorphous solid, [α]D
20 = +235.8 (c
1.2, CHCl3).
1H NMR (400 MHz, CDCl3): δ 5.03 (s, 1H,
OH), 3.86 (s, 3H, H-22), 3.82−3.73 (complex m, 1H, H-14),
3.52−3.47 (complex m, 1H, H-6), 3.37 (m, 1H, H-2), 2.70 (s,
1H), 2.65 (dd, J = 13.1 and 8.6 Hz, 1H), 2.32−2.19 (complex
m, 2H), 2.17−2.14 (complex m, 1H), 2.07−2.01 (complex m,
1H), 2.00−1.90 (complex m, 2H), 1.88−1.81 (complex m,
2H), 1.79−1.71 (complex m, 2H), 1.70−1.64 (complex m,
2H), 1.64−1.61 (complex m, 1H), 1.56−1.45 (complex m,
1H), 1.37−1.30 (complex m, 2H), 1.28 (d, J = 7.3 Hz, 3H, H-
1), 1.23 (t, J = 7.0 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ
199.8 (C16), 175.5 (C18), 167.6 (C19), 121.2 (C17), 80.3
(C20), 71.8 (C9), 69.1 (C14), 65.1 (C6), 55.2, 52.6, 52.2, 50.7,
49.8, 44.0, 43.5, 37.0, 34.1, 27.3, 26.9, 25.3, 24.4, 23.7. IR (KBr)
νmax: 3466, 2942, 2865, 1732, 1634, 1448, 1434, 1299, 1269,
1240, 1169, 1136, 1103, 1071, 1035, 1017, 989, 915, 877, 729,
646 cm−1. MS (ESI, +ve) m/z: 388 ([M + H]+, 100%), 410
([M + Na]+, 18). HRMS: [M + H]+ calcd for C22H30NO5,
388.2124; found, 388.2123.
Compound 25. Following a reported protocol,18 a magneti-
cally stirred mixture of ketone 24 (380 mg, 0.98 mmol) in Et2O
(5 mL) was treated with TCDI (530 mg, 3.0 mmol) and
DMAP (370 mg, 3.0 mmol). The solvent was evaporated, and
the resulting oil was heated at 80 °C for 5 h. The black residue
was subjected to chromatography (silica, 50:1 v/v CH2Cl2/
MeOH elution) to afford, after concentration of the relevant
fractions (Rf = 0.7), thionoester 25 (400 mg, 83%) as a yellow
amorphous solid, [α]D
20 = +215.5 (c 0.45, CHCl3).
1H NMR
(400 MHz, CDCl3): δ 8.27 (s, 1H, H-2″), 7.59 (s, 1H, H-4″),
6.99 (m, 1H, H-3″), 5.71 (m, 1H, H-14), 3.80 (s, 3H, H-22),
3.55 (m, 1H, H-6), 3.41 (m, 1H, H-2), 3.26 (dd, J = 13.5 and
9.6 Hz, 1H, H-15), 2.88 (s, 1H), 2.46−2.40 (complex m, 1H),
2.32−2.26 (complex m, 2H), 2.14 (m, 1H), 2.04−1.86
(complex m, 5H), 1.83−1.71 (complex m, 2H), 1.70−1.61
(complex m, 4H), 1.46−1.42 (complex m, 1H), 1.40 (d, J = 7.2
Hz, 3H), 1.37−1.35 (complex m, 1H). 13C NMR (100 MHz,
CDCl3): δ 193.3 (C16), 183.5 (C1″), 173.0 (C18), 167.5
(C19), 136.9 (C2″), 130.4 (C3″), 121.4 (C4″), 118.3 (C17),
81.0 (C14), 80.2 (C20), 69.3 (C9), 65.2 (C6), 55.4 (C2), 52.7,
50.1, 49.8, 49.5, 45.0, 43.8, 37.1, 30.8, 27.3, 26.5, 25.4, 24.9, 23.0
(C1). IR (KBr) νmax: 2946, 2864, 1734, 1648, 1464, 1384, 1333,
1285, 1235, 1166, 1095, 1043, 1027, 988, 907, 728, 653 cm−1.
MS (ESI, +ve) m/z: 498 ([M + H]+, 100%), 520 ([M + Na]+,
5). HRMS: [M + H]+ calcd for C26H32N3O5S, 498.2063; found,
498.2063.
GB24 (19). A magnetically stirred mixture of thionoester 25
(320 mg, 0.64 mmol) in dry toluene (20 mL) at 100 °C was
treated with AIBN (5.25 mg, 0.0032 mmol) and Bu3SnH (0.21
mL, 0.77 mmol). After stirring under the same temperature for
16 h, further portions of AIBN (10.5 mg, 0.0064 mmol) and
Bu3SnH (0.21 mL, 0.77 mmol) were added. The reaction
mixture was stirred for another 2 h before being concentrated
under reduced pressure. The resulting yellow residue was
subjected to chromatography (silica, 50:1 v/v CH2Cl2/MeOH
elution) to afford two fractions. Concentration of fraction A (Rf
= 0.55) gave GB24 (120 mg, 50%) as a white amorphous solid.
The structural data were, in all respects, similar to those of an
authentic sample from isolation work. Concentration of fraction
B (Rf = 0.50) gave a white amorphous solid tentatively
identified as ketone 24 (50 mg, 20%).
GB25 (16). A magnetically stirred mixture of compound 19
(100 mg, 0.27 mmol) in EtOH (6 mL) at 0 °C was treated with
NaBH4 (102 mg, 2.70 mmol). The mixture was stirred at the
same temperature for 2 h before being quenched by Na2CO3
(10 mL of a 1 M aqueous solution), and the solution was then
extracted by CH2Cl2 (3 × 50 mL). The combined organic
layers were dried (Na2SO4), filtered, and concentrated under
reduced pressure. The colouless oil was subjected to
chromatography (silica, 50:2 v/v CH2Cl2/MeOH elution) to
afford, after concentration of the relevant fractions (Rf = 0.4),
GB25 (75 mg, 75%) as a white amorphous solid. The structural
data were, in all respects, similar to those of an authentic
sample from isolation work.
GB14 (14). A magnetically stirred mixture of compound 16
(50 mg, 0.13 mmol) in pyridine (6 mL) was treated with Ac2O
(122 μL, 1.30 mmol) and DMAP (1.6 mg, 0.013 mmol). The
mixture was stirred and heated at 70 °C for 14 h before being
concentrated under high vacuum. The yellow oil so-formed was
subjected to chromatography (silica, 50:2 v/v CH2Cl2/MeOH
elution) to afford, after concentration of the relevant fractions
(Rf = 0.6), GB14 (40 mg, 71%) as a white amorphous solid.
The structural data were, in all respects, similar to those of an
authentic sample from isolation work.
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